Outlook Therapeutics, Inc. Email Format

Biotechnology ResearchNew Jersey, United States51-200 Employees

Outlook Therapeutics, Inc. is a mid-sized biotechnology company based in Cranbury, New Jersey, focused on developing and commercializing ophthalmic therapies for retinal diseases. Its lead candidate, ONS-5010/LYTENAVA (bevacizumab gamma), is an ophthalmic formulation of bevacizumab intended for conditions such as wet age-related macular degeneration. LYTENAVA has received marketing authorization in the European Union and the United Kingdom for wet AMD, and the company plans a commercial launch in the EU and UK in the second quarter of 2025. In the United States, ONS-5010/LYTENAVA remains investigational, with a BLA resubmission to the FDA, and if approved would be the first ophthalmic bevacizumab formulation approved for retinal indications. The company operates in the biotechnology research sector with a focus on expanding access to bevacizumab-based retinal therapy through European distribution and potential U.S. approval. A recent development in its European expansion was an exclusive distribution agreement with Mediconsult AG for LYTENAVA in Switzerland, announced in 2026.

Get verified Outlook Therapeutics, Inc. emails free

Company overview Employee directory